|
|
???tair.name??? >
???browser.page.title.title???
|
Showing items 718566-718575 of 2349128 (234913 Page(s) Totally)
<< < 71852 71853 71854 71855 71856 71857 71858 71859 71860 71861 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2022-02-08T06:27:20Z |
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
|
DA-LIANG OU; Chen C.-W.; Hsu C.-L.; Chung C.-H.; Feng Z.-R.; Lee B.-S.; Cheng A.-L.; Yang M.-H.; Hsu C. |
| 國立成功大學 |
2024 |
Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study
|
Kim;Y, J.;Merle;P;Finn;R, S.;Kudo;M;Kl�mpen;H, -J.;Lim;H, Y.;Ikeda;M;Alessandro;A;Masi;G;G�rolami;R;Cho;S, B.;Hsu;C, -H.;Huang;Y, -H.;Jeng;L, -B.;Kim;D, Y.;Lin;S, -M.;Pinter;M;Shao;G;Kato;N;Kurosaki;M;Numata;K;Kuo;K, -K.;Mao;Y;Lin;Y, -J.;Zhu;K;Twumasi-Ankrah;P;Khan;J;Awan;M;�zg�rdal;K;Qin;S |
| 臺大學術典藏 |
2021-08-31T06:29:40Z |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Bruix J.; Qin S.; Merle P.; Granito A.; Huang Y.-H.; Bodoky G.; Pracht M.; Yokosuka O.; Rosmorduc O.; Breder V.; Gerolami R.; Masi G.; Ross P.J.; Song T.; Bronowicki J.-P.; Ollivier-Hourmand I.; Kudo M.; ANN-LII CHENG; Llovet J.M.; Finn R.S.; LeBerre M.-A.; Baumhauer A.; Meinhardt G.; Han G. |
| 臺大學術典藏 |
2021-01-28T01:06:15Z |
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial
|
Xu J.; Xu R.-H.; Qin S.; Pan H.; Bai Y.; Chi Y.; Wang L.; Bi F.; Cheng Y.; Liu T.; Ma D.; Shen L.; Ba Y.; Liang J.; Wang X.; Yau T.C.C.; Ma B.B.; KUN-HUEI YEH; Lin J.-K.; Kappeler C.; Shapiro J.; Kalmus J.; Li J. |
| 臺大學術典藏 |
2018-09-10T15:17:40Z |
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial
|
Li, J. and Qin, S. and Xu, R. and Yau, T.C.C. and Ma, B. and Pan, H. and Xu, J. and Bai, Y. and Chi, Y. and Wang, L. and Yeh, K.-H. and Bi, F. and Cheng, Y. and Le, A.T. and Lin, J.-K. and Liu, T. and Ma, D. and Kappeler, C. and Kalmus, J. and Kim, T.W.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:31Z |
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial
|
Li J.; Qin S.; Xu R.; Yau T.C.C.; Ma B.; Pan H.; Xu J.; Bai Y.; Chi Y.; Wang L.; KUN-HUEI YEH; Bi F.; Cheng Y.; Le A.T.; Lin J.-K.; Liu T.; Ma D.; Kappeler C.; Kalmus J.; Kim T.W. |
| 國家衛生研究院 |
2022-03-10 |
Regorafenib reverses temozolomide-induced CXCL12/CXCR4 signaling and triggers apoptosis mechanism in glioblastoma
|
Chiang, IT;Liu, YC;Liu, HS;Ali, AAA;Chou, SY;Hsu, TI;Hsu, FT |
| 國立交通大學 |
2014-12-08T15:36:08Z |
RegPhos 2.0: an updated resource to explore protein kinase-substrate phosphorylation networks in mammals
|
Huang, Kai-Yao; Wu, Hsin-Yi; Chen, Yi-Ju; Lu, Cheng-Tsung; Su, Min-Gang; Hsieh, Yun-Chung; Tsai, Chih-Ming; Lin, Kuo-I; Huang, Hsien-Da; Lee, Tzong-Yi; Chen, Yu-Ju |
| 元智大學 |
2014-4-1 |
RegPhos 2.0: an updated resource to explore protein kinase-substrate phosphorylation networks in mammals
|
Kai-Yao Huang; Hsin-Yi Wu; Yi-Ju Chen; Cheng-Tsung Lu; Min-Gang Su; Yun-Chung Hsieh; Chih-Ming Tsai; Kuo-I Lin; Hsien-Da Huang; Tzong-Yi Lee; Yu-Ju Chen |
| 元智大學 |
2014-4-1 |
RegPhos 2.0: an updated resource to explore protein kinase-substrate phosphorylation networks in mammals
|
Kai-Yao Huang; Hsin-Yi Wu; Yi-Ju Chen; Cheng-Tsung Lu; Min-Gang Su; Yun-Chung Hsieh; Chih-Ming Tsai; Kuo-I Lin; Hsien-Da Huang; Tzong-Yi Lee; Yu-Ju Chen |
Showing items 718566-718575 of 2349128 (234913 Page(s) Totally)
<< < 71852 71853 71854 71855 71856 71857 71858 71859 71860 71861 > >>
View [10|25|50] records per page
|
